INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4565 participants.

Also called NCT02832544

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 4,565 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02832544
Other papers using this trial's data
  • Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation The New England journal of medicine, 2022-09-15 DOI, PubMed 36036525

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Botswana, Brazil, Cameroon, China, Egypt, Ethiopia, India, Kazakhstan, Kenya, Kyrgyzstan, Malawi, Mexico, Mozambique, Nepal, Nigeria, Pakistan, Paraguay, Philippines, Rwanda, South Africa, Sudan, Tanzania, Uganda, Zambia, Zimbabwe (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02832544. Randomized; no masking; primary purpose prevention. Start 2016-08-22 (actual); primary completion 2022-08-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority
Acronym
INVICTUS-VKA
Condition
Rheumatic Heart Disease
Intervention (Drug)
Rivaroxaban (20 mg)
Intervention (Drug)
Vitamin K antagonists (VKA)
Lead sponsor
Population Health Research Institute (class: other)
Collaborator
University of Cape Town (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02832544
Content hash
f8ba9b73873e5396d95eb94736bd7b62d7bfe9d8a8f3d37501a6ee23f5baea84